Efficacy of early administration of liposomal amphotericin B in patients with septic shock: A nationwide observational study.
J Infect Chemother
; 27(10): 1471-1476, 2021 Oct.
Article
em En
| MEDLINE
| ID: mdl-34183236
ABSTRACT
INTRODUCTION:
Liposomal amphotericin B (L-AMB), a broad spectrum anti-fungicidal drug, is often administered to treat invasive fungal infections (IFIs). However, the most suitable time to initiate treatment in septic shock patients with IFI is unknown.METHODS:
Patients with septic shock treated with L-AMB were identified from the Japanese Diagnosis Procedure Combination national database and were stratified according to L-AMB treatment initiation either at septic shock onset (early L-AMB group) or after the onset (delayed L-AMB group) to determine their survival rates following septic shock onset and the shock cessation period.RESULTS:
We identified 141 patients administered L-AMB on the day of or after septic shock onset 60 patients received early treatment, whereas 81 patients received delayed treatment. Survival rates after septic shock onset were higher in the early L-AMB group than in the delayed L-AMB group (4 weeks 68.4% vs 57.9%, P = 0.197; 6 weeks 62.2% vs 44.5%, P = 0.061; 12 weeks 43.4% vs 35.0%, P = 0.168, respectively). The septic shock cessation period was shorter in the early L-AMB group than in the delayed L-AMB group (7.0 ± 7.0 days vs 16.5 ± 15.4 days, P < 0.001), with a significant difference confirmed after adjusting for confounding factors with propensity score matching (7.1 ± 7.2 days vs 16.7 ± 14.0 days, P = 0.001).CONCLUSION:
Early L-AMB administration at septic shock onset may be associated with early shock cessation.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Choque Séptico
Tipo de estudo:
Observational_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article